---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-167481"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2024-06-25T23:59:59+00:00"
generated_at: "2026-06-01T02:12:40.880928+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences reports 46% mHTT lowering in HD trial; allele-selective silencing demonstrated

## Summary
- SELECT-HD: 30 mg WVE-003 Q8W showed 46% mean mHTT reduction vs placebo at 24 weeks (p=0.0007); 44% at 28 weeks (p=0.0002).
- Wild-type HTT preserved; allele-selective silencing confirmed.
- mHTT reduction correlated with slowing of caudate atrophy (R=-0.50, p=0.047), an imaging biomarker predictive of clinical outcomes.
- Generally safe and well-tolerated; no serious adverse events reported.
- Cash runway into Q4 2025; Wave to discuss accelerated approval path with regulators.

## SEC filing metadata
- accession: 0001193125-24-167481
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2024-06-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312524167481/0001193125-24-167481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312524167481/d771392d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-167481
- JSON: https://secwatch.observer/filing/0001193125-24-167481.json
- Plain text: https://secwatch.observer/filing/0001193125-24-167481.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.